Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Kleo Pharmaceuticals

  • Doug Manion, Kleo Pharmaceuticals

Kleo Pharmaceuticals is a unique immuno-oncology company developing next-generation bispecific compounds designed to emulate or enhance the activity of biologics. Similar to complex biologic drugs, Kleo’s compounds recruit the immune system to destroy cancer cells, but unlike biologics, Kleo’s compounds are smaller and more versatile, leading to potentially improved safety and efficacy. They are also much faster and less costly to design and produce, particularly against novel targets. The company is advancing several drug candidates based on its proprietary technology platforms, all of which are modular in design and enable rapid generation of novel immunotherapies that can be optimized against certain cancers, or enhance the properties of existing immunotherapies. These include Antibody Recruiting Molecules (ARMs), Synthetic Antibody Mimics (SyAMs) and Monoclonal Antibody Therapy Enhancers (MATEs). For more information visit http://kleopharmaceuticals.com.

  • Date:Monday, February 11
  • Time:3:30 PM - 3:45 PM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23516
  • Goal for Presentation:Corporate update, investor awareness
  • Company Website:www.kleopharmaceuticals.com
  • Company HQ City:New Haven
  • Company HQ State:Connecticut
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$34M
  • Size of Last Investment Round:$21M
  • CEO/Top Company Official:Doug Manion, M.D. FRCP(C)
  • Year Founded:2015
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:ARMs, SyAMs, MATEs
  • Development Phase of Primary Product:Pre-Clinical
Speakers
Doug Manion
Kleo Pharmaceuticals
Back